Mark Lewis shared a tweet by Yüksel Ürün on X, adding the following:
“Once again, we have got to normalize biomarker-driven selection of care in colorectal cancer the same way we have standardized it in breast cancer.”
Quoting Yüksel Ürün’s post:
“Progress extends survival and personalizes care.”
Authors: Paolo Ciracì, Vittorio Studiale, Ada Taravella, Carlotta Antoniotti & Chiara Cremolini
Mark Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent and young adult (AYA) oncology in the SWOG cooperative group, and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer. His interests are neuroendocrine tumors and cancer syndromes.
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.